Effect of Nava on Weaning Outcome in Patients With Mechanical Ventilation
NCT ID: NCT05219643
Last Updated: 2025-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
130 participants
INTERVENTIONAL
2021-10-15
2025-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of NAVA on Weaning Duration in Difficult to Wean Patients
NCT01280773
NAVASET: Nava Level Titration Using Comfort Scales
NCT02133443
Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure
NCT01730794
Pressure Support Ventilation Versus Neurally Adjusted Ventilatory Assist in Difficult to Wean Pediatric Patients
NCT04360590
Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.
NCT01928238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is a prospective, multicenter, parallel group, single blind, randomized controlled tria。
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NAVA
Received NAVA.
NAVA
Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
PSV
Received PSV.
PSV
According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NAVA
Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
PSV
According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. When support pressure ≤ 15 cmH2O, it can withstand pressure support ventilation (PSV) time \> 1h;
Exclusion Criteria
2. Deep sedation.
3. Severe hemodynamic instability (norepinephrine or equivalent converted dose of other vasoactive drugs \> 1ug / kg.min or map ≤ 65mmhg)
4. Severe respiratory center depression, high paraplegia, neuromuscular disease;
5. Esophageal obstruction, esophageal perforation, severe esophageal variceal bleeding, upper gastrointestinal surgery, diaphragmatic hernia and thoracic deformity;
6. Patients with chronic respiratory diseases requiring long-term home oxygen therapy;
7. Patients with severe coagulation dysfunction (INR \> 1.5, APTT \> 44s, history of leukemia);
8. Severe other organ dysfunction is expected to die in a short time (7 days) or palliative treatment.
9. The estimated survival time of advanced solid organ or hematological system tumors is \< 30 days
10. Participate in other clinical studies within 30 days;
11. Failing to sign the informed consent form;
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Wannan Medical College
OTHER
Southeast University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ling Liu
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liu Ling, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongda Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAVA2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.